A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
about
Adjuvant chemotherapy for resected early-stage non-small cell lung cancerAntiangiogenesis cocktails - stirred or shaken?Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in JapanNon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipAdjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.Prognostic gene signatures for non-small-cell lung cancer.An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: a report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901.Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.Transcriptional network classifiersAdjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataSafety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trialAdjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial DataImpact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage IA non-small cell lung cancerProposal of an improved histological sub-typing system for lung adenocarcinoma - significant prognostic values for stage I disease.Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinomaA dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.Advances in adjuvant systemic therapy for non-small-cell lung cancer.Adjuvant chemotherapy of non-small cell lung cancer.Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?Time-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 Chinese patients.SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells.Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cellsA transcriptional network signature characterizes lung cancer subtypesAdjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer.Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trialIdentification of the NEDD4L gene as a prognostic marker by integrated microarray analysis of copy number and gene expression profiling in non-small cell lung cancer.Varied pathways of stage IA lung adenocarcinomas discovered by integrated gene expression analysisNew challenges and inspired answers for anticancer drug discovery and developmentFavorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studiesCyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients
P2860
Q24187439-D8895346-9E60-4DEC-9A85-3FD66991B325Q24548357-2B3A15ED-3EA6-4289-9751-D4AF8A4D3511Q24633384-C2677A11-B7E5-4CD7-9F34-C94AB18BCB39Q28278682-823512C7-678D-4DAF-A8D1-E0559459A828Q30438068-A09BD130-B8BD-4F54-A1A7-8A29628B670AQ30439235-6D8E4D9F-A13D-4B45-8116-8181747851AEQ30485836-658EA828-8799-4F3A-95CA-25176E1C7D1DQ31106341-984291CF-50AC-48B2-9942-6848D602EC3EQ33405513-C00280A9-43E4-44CE-AB1F-11B034FD5BE8Q33437409-EEA6DD33-3388-4E03-9058-96DDFBA07CCCQ33504356-90C06870-4009-4B56-B5F3-EF21408942E2Q33546241-32BC11AD-E129-4B43-AB7A-6934A3DEC5B9Q33656724-3F8F9060-75DF-495A-B709-59530FB9FFDFQ33703679-820BC0E2-135E-43BF-86AF-EDF29FE9F015Q33728605-F2ACD109-A21E-4017-BC77-1EA4DC391B32Q33759505-C2BD7CE2-1EB4-40D2-86F5-EC96523EF7DAQ33861078-EFC5E1A8-1455-4D35-AB07-C189102E3F54Q33877902-B6692A82-DF1E-4A2D-9531-570CEFC36A77Q33884698-A5422F94-0F74-4B21-B963-07631E30F361Q33967458-6751231E-6D5C-4750-B2EE-6569CCFD30ECQ33974932-027DB81F-6084-4CD2-99F8-BB5D8BF5AA86Q34031225-1A1EFD63-0C83-4BD7-B632-CCF091479AD1Q34126484-1DC9641A-39EB-44E3-9FA4-3E10304043EEQ34143336-C6D3011D-6527-489D-96ED-EDEFE15F6DE2Q34155998-E6BF9BA2-49D7-4C16-9B36-F0DAC03F438BQ34277248-A2796A76-2022-4E72-B2E7-3D930154C507Q34300621-5C7A7021-4750-444B-A2CD-6B7F7CDD2B80Q34408058-09A1B395-580E-4D9C-84C0-FAE91DB11681Q34472310-6CFA0806-BD05-47F5-B8EF-FDE4064DD51AQ34479081-4A260004-D574-4EBD-91AA-76C157DE5A26Q34497992-162D648B-DBEE-498F-B708-8C50FF4C4FF2Q34627201-3664C8CC-3F0C-45AA-91EC-419501B7E870Q34633657-EB07131B-A908-4FA7-ADA9-92EEF7050D18Q34747013-A93E8E3D-7154-47B9-951C-F693790C9C46Q34787147-1EC2266E-8F4D-4014-A523-41B821B1F5A6Q34941004-85DFF08A-461D-4BBE-8DDE-C95DEFB1207BQ34981175-67C96A23-E87A-41D4-87B5-5678F6F38053Q35073353-BC111244-CCD9-4AC6-BABE-D00F568CA8CCQ35096604-BE76C978-1B84-41A7-9996-A1FF794993F7Q35196367-721637D5-7112-4CCE-80D3-B0F0EEF3682B
P2860
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@ast
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@en
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@nl
type
label
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@ast
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@en
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@nl
prefLabel
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@ast
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@en
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@nl
P2093
P3181
P356
P1476
A randomized trial of adjuvant ...... for adenocarcinoma of the lung
@en
P2093
Harubumi Kato
Hirohito Tada
Hiromi Wada
Masahiro Tsuboi
Mitsuo Ohta
Morio Ohta
Nobuyuki Hamajima
Noriaki Tsubota
Yoh Watanabe
P304
P3181
P356
10.1056/NEJMOA032792
P407
P577
2004-04-22T00:00:00Z